Tycel Phillips, MD, on the Role of Targeted Therapies in Frontline MCL
By Leah Sherwood - Last Updated: February 1, 2023Tycel Phillips, MD, discusses the role of targeted therapies in frontline mantel cell lymphoma (MCL) in this video interview with Blood Cancers Today.
Advertisement
Post Tags:SOHO 2022
Advertisement
Related Posts
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
Clinical evaluations of this bispecific antibody as monotherapy or in polytherapy for B-cell non-Hodgkin lymphomas continue.
This new approval adds upon the agent's indications for relapsed or refractory DLBCL and other large B-cell lymphomas.
Dr. Phillips discussed the phase II TRIANGLE study, the shifting role of HSCT, and unmet needs in high-risk patients.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.